Emerging Data for HER2 ADCs in Ovarian Cancer
Ritu Salani, MD, presents an outline of the treatment landscape for ovarian cancer and underscores encouraging data from the DESTINY-PanTumor02 study, showcasing promising results in this treatment setting.
EP: 1.Exploring HER2 as a Pan Tumor Biomarker
EP: 2.HER2 in Breast Cancer: Shaping Treatment in Other Solid Tumors
EP: 3.Expert Insights on HER2-Directed ADCs in Breast Cancer
EP: 4.Targeting HER2 Alterations with ADCs in NSCLC
EP: 5.Landscape Surrounding HER2 ADCs in GI Cancers
EP: 6.Emerging Data for HER2 ADCs in Ovarian Cancer
EP: 7.HER2 ADCs in Endometrial Cancer: Shaping the Treatment Landscape
EP: 8.HER2 ADCs in Cervical Cancer: A Promising Therapeutic Frontier
EP: 9.Expert Insights on HER2 Testing in Gynecological Cancers
EP: 10.Future Perspectives on HER2 ADCs in Gynecological Cancer
Dr. Ritu Salani discusses the impact of HER2-directed antibody-drug conjugates (ADCs) in gynecologic oncology, focusing on the DESTINY-PanTumor02 trial and its implications for ovarian cancer.
The DESTINY-PanTumor02 trial enrolled patients with HER2 expression (3+ and some 2+) who were in the second-line setting or beyond. For ovarian cancer, platinum and taxane-based chemotherapy, along with PARP inhibitors and bevacizumab, are highly effective in the front-line setting, with response rates over 80% in advanced stages. However, recurrence rates remain high at 80%.
Previous studies of trastuzumab in ovarian cancer showed extremely low response rates, and HER2-targeted therapy never gained much attention in this space. The DESTINY-PanTumor02 trial reported an overall response rate of 45% in ovarian cancer patients with HER2 expression, which is a significant improvement compared to the 20% response rate typically seen in platinum-resistant disease. Patients with IHC 3+ expression had an even higher response rate of 63-64%.
At the 14-month follow-up presented at ASCO, the trial reported a median progression-free survival of 12 months, which is more impressive than any other treatment to date. Dr. Salani emphasizes the need to understand the details of these patients' chemo-responsiveness, which will be important once the manuscript is fully vetted.
These results have piqued interest in the gynecologic oncology community, and Dr. Salani believes that this approach definitely warrants further exploration, particularly for patients with 3+ HER2 expression.
Summary generated by Claude AI.
